Emerging Diabetes Drugs

Product description

The Competitive Intelligence Report Emerging Diabetes Drugs & Targets as of November 2008 provides a competitor analysis in the development pipeline of novel emerging antidiabetic treatment modalities for type 1 and 2 diabetes beyond the established targets PPAR agonists, DPP-IV inhibitors, GLP-1 receptor agonists and SGLT inhibitors. The report also includes the diabetes R&D portfolios of those companies with emerging diabetes drugs (incl. R&D projects for established targets).

Emerging diabetes treatment modalities were assigned to four different clusters:

• Metabolic Approaches
• Pancreatic Islet Cell Approaches
• Cell Therapy
• Anti-Inflammatory Approaches

The majority of emerging diabetes drugs still is derived from metabolic approaches:

• Protein Tyrosine Phosphatase 1B (PTP-1B) Inhibitors I
• Glucokinase Activators
• 11-beta Hydroxysteroid Dehydrogenase type-1 (HSD-1) Inhibitors I
• Adenosine 5' monophosphate (AMP)-activated Protein Kinase (AMPK) Activators I
• Glucagon Receptor Agonists & Antagonists
• Glucocorticoid Receptor Agonists & Antagonists
• Glucose-Dependent Insulinotropic Receptor (GDIR) Activators I
• Ghrelin Receptor Antagonists
• FGF-21 Approaches
• Inhibitors of Gluconeogenese
• Various Gluco-Metabolic Approaches -I
• Various Lipo-Metabolic Approaches
• Repositioning Approaches

A rising number of new approaches is directed at the pancreatic islet cell mass and function:

• SIRT
• Gastrin-based Approaches for beta Cell Regeneration
• Preservation of beta Cell Capacity to Produce Insulin
• Vaccines to Prevent Destruction of beta Cells
• Antibodies to Prevent Destruction of beta Cells

The report describes commercial R&D activites in cell therapy of islet cell transplantation and provides information on anti-inflammatory approaches including interleukin-1 (IL-1) directed therapies.

The Competitor Analysis Emerging Diabetes Drugs & Targets also provides the Diabetes Drug R&D pipelines of major players from Big Pharma and specialty biotech companies.

The report includes a compilation of current active projects in research and development of emerging diabetes drugs. Competitor projects are listed in a tabular format providing Information on:

• Drug Codes,
• Target / Mechanism of Action,
• Class of Compound,
• Company,
• Product category,
• Indication,
• R&D Stage and
• Additional comments with a hyperlink leading to the source of information.